ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
결절성 경화증 치료제 시장 규모는 향후 몇 년 동안 강력한 성장세를 보일 것으로 예상되며, 2029년까지 연평균 8.4%의 성장률(CAGR)로 11억 9,000만 달러에 달할 것으로 예측됩니다. 예측 기간 동안 예상되는 성장의 원동력은 맞춤형 의료에 대한 관심 증가, 희귀질환 치료제 개발 투자 증가, 환자 옹호 및 지원 네트워크 확대, 카나비디올 기반 치료법의 출현, 유전자 표적 치료의 발전 등으로 예상됩니다. 예측 기간을 형성할 것으로 예상되는 주요 동향으로는 병용요법 접근법의 성장, 희귀질환 치료제 규제 신속화, 칸나비디올(에피디올렉스) 채택 증가, 질병 변형 치료법 개발, 결절성 경화증 복합체(TSC) 관리에 있어 디지털 헬스 기술 통합 등이 있습니다.
만성질환의 유병률 증가는 향후 몇 년간 결절성 경화증 치료제 시장 확대에 크게 기여할 것으로 예측됩니다. 만성질환은 서서히 발병하고 지속적인 치료가 필요한 장기적인 질환을 말합니다. 여기에는 당뇨병, 심장병, 고혈압, 관절염, 만성 호흡기 질환, 암, 비만 등이 포함됩니다. 이러한 질병 증가는 건강에 해로운 식습관이나 운동 부족과 같은 생활습관 요인에 기인하는 바가 크며, 장기적인 건강 합병증을 유발합니다. 결절성 경화증 치료제는 결절성 경화증 복합체(TSC)의 근본 원인을 해결하고 종양 억제 및 발작 조절을 위한 효과적인 옵션을 제공함으로써 만성 질환 관리를 지원합니다. 이러한 약물은 장기적인 증상 관리를 가능하게 하고 병원 방문 빈도를 줄여 환자의 예후를 개선할 수 있습니다. 예를 들어, 2024년 6월 영국 국민보건서비스(NHS)는 일반 개업의에 등록된 환자 중 2023년 비당뇨병성 고혈당증 또는 당뇨병 예비군으로 진단받은 환자가 361만 5,330명으로 2022년 306만 5,825명에서 18% 증가했다고 보고했습니다. 결과적으로 만성질환 유병률 증가가 결절성 경화증 치료제 시장의 성장을 가속하고 있습니다.
결절성 경화증 치료제 시장의 기업들은 포유류 라파마이신 표적(mTOR) 억제제 등 종양 축소, 발작 억제, 근본적인 질병 기전 규명을 목표로 하는 치료제 개발을 통해 혁신에 집중하고 있습니다. 하는 mTOR 단백질을 차단하는 의약품의 일종입니다. 예를 들어, 2024년 8월 미국 제약사 Upsher-Smith Laboratories LLC는 결절성 경화증 복합체(TSC) 환자를 위해 2.5mg, 5mg, 7.5mg, 10mg의 다양한 강도의 TORPENZ(에버로리무스) 정제를 출시했습니다. 토르펜즈는 TSC에서 비정상적인 세포 증식을 유발하는 과도한 mTOR 경로를 억제하여 양성 종양을 축소하고, 발작 등 관련 증상을 조절하는 데 도움을 줍니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계 결절성 경화증 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 결절성 경화증 치료제 시장 : 성장률 분석
세계의 결절성 경화증 치료제 시장 실적 : 규모와 성장, 2019-2024
세계의 결절성 경화증 치료제 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계 결절성 경화증 치료제 전체 시장(TAM)
제6장 시장 세분화
세계의 결절성 경화증 치료제 시장 : 약제 클래스별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
표적치료
면역치료
치료
세계의 결절성 경화증 치료제 시장 : 투여 경로별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
경구
정맥내
피하
세계의 결절성 경화증 치료제 시장 : 치료 단계별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
초기 진단
만성질환 관리
재발 관리
세계의 결절성 경화증 치료제 시장 : 유통 채널별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
세계의 결절성 경화증 치료제 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원
홈케어
전문 클리닉
기타 최종사용자
세계의 결절성 경화증 치료제 시장 : 표적치료 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 결절성 경화증 치료제 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 결절성 경화증 치료제 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
결절성 경화증 치료제 시장 : 경쟁 구도
결절성 경화증 치료제 시장 : 기업 개요
Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
The Johns Hopkins University : 개요, 제품 및 서비스, 전략 및 재무 분석
Yale University : 개요, 제품 및 서비스, 전략 및 재무 분석
Jazz Pharmaceuticals Public Limited Company : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Washington University School of Medicine
Dr. Reddy's Laboratories
H. Lundbeck A/S
Shijiazhuang Yiling Pharmaceutical Co. Ltd
BridgeBio Pharma Inc.
Globela Pharma Pvt Ltd.
Noema Pharma AG
Aucta Pharmaceuticals Inc.
Aeovian Pharmaceuticals Inc.
Anavex Life Sciences Corp.
Aucta Pharmaceuticals Inc.
Par Pharmaceutical
GRIN Therapeutics Inc.
Ovid Therapeutics Inc.
Cassava Sciences Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
결절성 경화증 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
결절성 경화증 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
결절성 경화증 치료제 시장(2029년) : 성장 전략
시장 동향에 근거한 전략
경쟁 전략
제36장 부록
LSH
영문 목차
영문목차
Tuberous sclerosis drugs are medications used to treat the symptoms of tuberous sclerosis complex (TSC), a genetic disorder that leads to the formation of benign tumors in various organs, particularly the brain, kidneys, heart, lungs, and skin. The primary objective of these treatments is to reduce tumor size, control seizures, and manage related symptoms, ultimately enhancing the quality of life by addressing the underlying cellular abnormalities.
The main classes of drugs used in tuberous sclerosis treatment include targeted therapy, immunotherapy, and symptomatic treatments. Targeted therapy involves using medications that specifically focus on molecular pathways responsible for tumor growth in TSC. These drugs can be administered through various routes, including oral, intravenous, and subcutaneous methods. Treatment generally occurs in stages, such as initial diagnosis, chronic management, and management of recurrent symptoms. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies, with end-users including hospitals, home care providers, specialty clinics, and others.
The tuberous sclerosis drug market research report is one of a series of new reports from The Business Research Company that provides tuberous sclerosis drug market statistics, including tuberous sclerosis drug industry global market size, regional shares, competitors with a tuberous sclerosis drug market share, detailed tuberous sclerosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the tuberous sclerosis drug industry. This tuberous sclerosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The tuberous sclerosis drug market size has grown strongly in recent years. It will grow from $0.79 billion in 2024 to $0.86 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth observed during the historic period can be attributed to the increasing awareness of rare genetic disorders, the rising prevalence of epilepsy among tuberous sclerosis complex (TSC) patients, higher rates of clinical diagnosis, the availability of anticonvulsants, and expanding research on neurocutaneous syndromes.
The tuberous sclerosis drug market size is expected to see strong growth in the next few years. It will grow to $1.19 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The anticipated growth in the forecast period is expected to be driven by a greater focus on personalized medicine, increased investment in the development of drugs for rare diseases, the expansion of patient advocacy and support networks, the emergence of cannabidiol-based treatments, and the progress in gene-targeted therapies. Key trends expected to shape the forecast period include the growth of combination therapy approaches, regulatory fast-tracking for rare disease drugs, rising adoption of cannabidiol (Epidiolex), the development of disease-modifying therapies, and the integration of digital health technologies in the management of tuberous sclerosis complex (TSC).
The growing incidence of chronic diseases is expected to significantly contribute to the expansion of the tuberous sclerosis drug market in the coming years. Chronic diseases are long-lasting medical conditions that usually develop gradually and require continuous care. These include diabetes, heart disease, hypertension, arthritis, chronic respiratory conditions, cancer, and obesity. The rise in these diseases is largely attributed to lifestyle factors such as unhealthy diets and physical inactivity, which lead to long-term health complications. Tuberous sclerosis drugs support chronic disease management by addressing the root causes of tuberous sclerosis complex (TSC), offering effective options for tumor suppression and seizure control. These medications improve patient outcomes by enabling long-term symptom management and reducing the frequency of hospital visits. For instance, in June 2024, the UK's National Health Service (NHS) reported that 3,615,330 individuals registered with general practitioners were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023-an 18% increase from 3,065,825 cases in 2022. As a result, the increasing incidence of chronic diseases is propelling the growth of the tuberous sclerosis drug market.
Companies in the tuberous sclerosis drug market are focusing on innovation through the development of treatments such as mammalian target of rapamycin (mTOR) inhibitors to reduce tumor size, control seizures, and target the underlying disease mechanisms. mTOR inhibitors are a class of medications that block the mTOR protein, which regulates key cellular processes including growth, proliferation, and survival. For example, in August 2024, Upsher-Smith Laboratories LLC, a U.S.-based pharmaceutical firm, introduced TORPENZ (everolimus) tablets in multiple strengths-2.5 mg, 5 mg, 7.5 mg, and 10 mg-for patients with tuberous sclerosis complex (TSC). TORPENZ functions by inhibiting the overactive mTOR pathway responsible for abnormal cell growth in TSC, helping to shrink benign tumors and manage associated symptoms such as seizures.
In February 2025, Immedica Pharma AB, a Sweden-based pharmaceutical company, acquired Marinus Pharmaceuticals Inc. for $151 million. This acquisition aims to expand Immedica's footprint in the rare seizure disorder segment and enhance its neuroscience drug portfolio, particularly with the inclusion of ganaxolone. The move supports Immedica's strategic objective to broaden its global presence and strengthen its pipeline for treating rare central nervous system (CNS) conditions. Marinus Pharmaceuticals Inc., based in the U.S., is a biopharmaceutical company focused on developing innovative therapies for rare seizure disorders, including those linked to tuberous sclerosis.
Major players in the tuberous sclerosis drug market are Johnson & Johnson, Novartis AG, The Johns Hopkins University, Yale University, Jazz Pharmaceuticals Public Limited Company, Washington University School of Medicine, Dr. Reddy's Laboratories, H. Lundbeck A/S, Shijiazhuang Yiling Pharmaceutical Co. Ltd, BridgeBio Pharma Inc., Globela Pharma Pvt Ltd., Noema Pharma AG, Aucta Pharmaceuticals Inc., Aeovian Pharmaceuticals Inc., Anavex Life Sciences Corp., Aucta Pharmaceuticals Inc., Par Pharmaceutical, GRIN Therapeutics Inc., Ovid Therapeutics Inc., and Cassava Sciences Inc.
North America was the largest region in the tuberous sclerosis drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tuberous sclerosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the tuberous sclerosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The tuberous sclerosis drug market consists of sales of topical treatments, psychiatric medications, and supportive care therapies used to manage the various symptoms and complications of tuberous sclerosis complex. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Tuberous Sclerosis Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on tuberous sclerosis drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for tuberous sclerosis drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tuberous sclerosis drug market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Drug Class: Targeted Therapy; Immunotherapy; Symptomatic Treatment
2) By Route Of Administration: Oral; Intravenous; Subcutaneous
3) By Treatment Stage: Initial Diagnosis; Chronic Management; Recurrent Management
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End-Users
Subsegments:
1) By Targeted Therapy: Mammalian Target Of Rapamycin (mTOR) Inhibitors; Vascular Endothelial Growth Factor (VEGF) Inhibitors; Tyrosine Kinase Inhibitors
2) By Immunotherapy: Monoclonal Antibodies; Immune Checkpoint Inhibitors; Cytokine Therapy
3) By Symptomatic Treatment: Antiepileptic Drugs; Corticosteroids; Behavioral Therapy Medications
Companies Mentioned: Johnson & Johnson; Novartis AG; The Johns Hopkins University; Yale University; Jazz Pharmaceuticals Public Limited Company
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Tuberous Sclerosis Drug Market Characteristics
3. Tuberous Sclerosis Drug Market Trends And Strategies
4. Tuberous Sclerosis Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Tuberous Sclerosis Drug Growth Analysis And Strategic Analysis Framework
5.1. Global Tuberous Sclerosis Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Tuberous Sclerosis Drug Market Growth Rate Analysis
5.4. Global Tuberous Sclerosis Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Tuberous Sclerosis Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Tuberous Sclerosis Drug Total Addressable Market (TAM)
6. Tuberous Sclerosis Drug Market Segmentation
6.1. Global Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Targeted Therapy
Immunotherapy
Symptomatic Treatment
6.2. Global Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Subcutaneous
6.3. Global Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Initial Diagnosis
Chronic Management
Recurrent Management
6.4. Global Tuberous Sclerosis Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Tuberous Sclerosis Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Homecare
Specialty Clinics
Other End-Users
6.6. Global Tuberous Sclerosis Drug Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
6.7. Global Tuberous Sclerosis Drug Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Monoclonal Antibodies
Immune Checkpoint Inhibitors
Cytokine Therapy
6.8. Global Tuberous Sclerosis Drug Market, Sub-Segmentation Of Symptomatic Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antiepileptic Drugs
Corticosteroids
Behavioral Therapy Medications
7. Tuberous Sclerosis Drug Market Regional And Country Analysis
7.1. Global Tuberous Sclerosis Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Tuberous Sclerosis Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Tuberous Sclerosis Drug Market
8.1. Asia-Pacific Tuberous Sclerosis Drug Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Tuberous Sclerosis Drug Market
9.1. China Tuberous Sclerosis Drug Market Overview
9.2. China Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Tuberous Sclerosis Drug Market
10.1. India Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Tuberous Sclerosis Drug Market
11.1. Japan Tuberous Sclerosis Drug Market Overview
11.2. Japan Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Tuberous Sclerosis Drug Market
12.1. Australia Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Tuberous Sclerosis Drug Market
13.1. Indonesia Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Tuberous Sclerosis Drug Market
14.1. South Korea Tuberous Sclerosis Drug Market Overview
14.2. South Korea Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Tuberous Sclerosis Drug Market
15.1. Western Europe Tuberous Sclerosis Drug Market Overview
15.2. Western Europe Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Tuberous Sclerosis Drug Market
16.1. UK Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Tuberous Sclerosis Drug Market
17.1. Germany Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Tuberous Sclerosis Drug Market
18.1. France Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Tuberous Sclerosis Drug Market
19.1. Italy Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Tuberous Sclerosis Drug Market
20.1. Spain Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Tuberous Sclerosis Drug Market
21.1. Eastern Europe Tuberous Sclerosis Drug Market Overview
21.2. Eastern Europe Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Tuberous Sclerosis Drug Market
22.1. Russia Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Tuberous Sclerosis Drug Market
23.1. North America Tuberous Sclerosis Drug Market Overview
23.2. North America Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Tuberous Sclerosis Drug Market
24.1. USA Tuberous Sclerosis Drug Market Overview
24.2. USA Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Tuberous Sclerosis Drug Market
25.1. Canada Tuberous Sclerosis Drug Market Overview
25.2. Canada Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Tuberous Sclerosis Drug Market
26.1. South America Tuberous Sclerosis Drug Market Overview
26.2. South America Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Tuberous Sclerosis Drug Market
27.1. Brazil Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Tuberous Sclerosis Drug Market
28.1. Middle East Tuberous Sclerosis Drug Market Overview
28.2. Middle East Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Tuberous Sclerosis Drug Market
29.1. Africa Tuberous Sclerosis Drug Market Overview
29.2. Africa Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Tuberous Sclerosis Drug Market Competitive Landscape And Company Profiles
30.1. Tuberous Sclerosis Drug Market Competitive Landscape
30.2. Tuberous Sclerosis Drug Market Company Profiles
30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
30.2.3. The Johns Hopkins University Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Yale University Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Jazz Pharmaceuticals Public Limited Company Overview, Products and Services, Strategy and Financial Analysis
31. Tuberous Sclerosis Drug Market Other Major And Innovative Companies
31.1. Washington University School of Medicine
31.2. Dr. Reddy's Laboratories
31.3. H. Lundbeck A/S
31.4. Shijiazhuang Yiling Pharmaceutical Co. Ltd
31.5. BridgeBio Pharma Inc.
31.6. Globela Pharma Pvt Ltd.
31.7. Noema Pharma AG
31.8. Aucta Pharmaceuticals Inc.
31.9. Aeovian Pharmaceuticals Inc.
31.10. Anavex Life Sciences Corp.
31.11. Aucta Pharmaceuticals Inc.
31.12. Par Pharmaceutical
31.13. GRIN Therapeutics Inc.
31.14. Ovid Therapeutics Inc.
31.15. Cassava Sciences Inc.
32. Global Tuberous Sclerosis Drug Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Tuberous Sclerosis Drug Market
34. Recent Developments In The Tuberous Sclerosis Drug Market
35. Tuberous Sclerosis Drug Market High Potential Countries, Segments and Strategies
35.1 Tuberous Sclerosis Drug Market In 2029 - Countries Offering Most New Opportunities
35.2 Tuberous Sclerosis Drug Market In 2029 - Segments Offering Most New Opportunities
35.3 Tuberous Sclerosis Drug Market In 2029 - Growth Strategies
35.3.1 Market Trend Based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer
(주)글로벌인포메이션02-2025-2992kr-info@giikorea.co.kr ⓒ Copyright Global Information, Inc. All rights reserved.
